Every material Form 8-K Alnylam Pharmaceuticals filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alnylam Pharmaceuticals said its Executive Vice President, Chief Legal Officer and Secretary, Indrani L. Franchini, stepped down from that role effective March 1, 2024, as previously reported in January. Under a separation agreement, she receives severance of $597,000 and other benefits, and will provide consulting services through March 1, 2025.
Separation date: March 1, 2024; Franchini was Executive Vice President, Chief Legal Officer and Secretary.
Severance totals $597,000, paid as twelve months of base salary in bi-weekly installments, plus a 2023 annual incentive payment adjusted by the Board's corporate multiplier.
Consulting period runs until March 1, 2025; hours above ten per month are paid at $500 per hour, and unvested equity awards continue to vest.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alnylam Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →